bsc

US-based Boston Scientific has received CE Mark approval for its next-generation bare metal stent, REBEL platinum chromium coronary stent system, designed to treat coronary artery disease (CAD).

The REBEL stent system offers physicians the same platform as the Promus PREMIER drug eluting stent (DES), but without the Everolimus drug.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The customised platinum chromium alloy stent features unparalleled visibility, low recoil, exceptional radial strength and fracture resistance, while improving axial strength and deliverability.

The enhanced low-profile delivery system features a shorter, more visible tip, a unique dual-layer balloon and a Bi-Segment inner lumen catheter, which provides an appropriate level of pushability and flexibility to create enhanced deliverability.

Investigator for the OMEGA clinical trial professor Dr Didier Carrie said: "I am glad to have a bare metal stent that performs like the PREMIER DES but allows me to treat patients who are not candidates for DES therapy.

See Also:

"In addition to its great visibility and deliverability, the platinum chromium stent architecture features low recoil that is particularly important for patients treated with bare metal stents."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

OMEGA is a single-arm, multi-centre trial designed to assess the platinum chromium bare metal stent system in the US and Europe. The trial data is expected to support the FDA regulatory submission.

"I am glad to have a bare metal stent that performs like the PREMIER DES but allows me to treat patients who are not candidates for DES therapy."

In February, Dr John C Wang of Medstar Union Memorial Hospital, Baltimore, Maryland, presented the trial data from OMEGA at the Cardiovascular Research Technologies conference in Washington, DC.

Boston Scientific interventional cardiology president Kevin Ballinger said the company is committed to advancing cardiology and providing treatment options for all patients with CAD.

"This includes innovating and improving the performance of bare metal stent technology to enhance patient outcomes," Ballinger said.

The REBEL stent system is currently available on a Monorail platform in a matrix of 48 sizes, ranging in diameter from 2.25mm to 4.50mm and lengths of 8mm to 32mm. This provides physicians with a range of options designed to best suit patient needs.

According to the company, bare metal stents continue to play a vital role in the treatment of CAD and represent a significant portion of the global stent market.

The REBEL stent system is currently an investigational device and not available for sale in the US.

Image: Boston Scientific’s corporate headquarters in Natick, Massachusetts. Photo: courtesy of Boston Scientific Corp.